Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M110Revenue $M23.2Net Margin (%)-101.9Altman Z-Score-5.8
Enterprise Value $M95.7EPS $-1.4Operating Margin %-92.9Piotroski F-Score3
P/E(ttm)--Beneish M-Score-3.3Pre-tax Margin (%)-101.7Higher ROA y-yY
Price/Book4.310-y EBITDA Growth Rate %--Quick Ratio2.0Cash flow > EarningsY
Price/Sales4.15-y EBITDA Growth Rate %--Current Ratio2.3Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %-376.0ROA % (ttm)-49.4Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-130.9Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M20.2ROIC % (ttm)-139.7Gross Margin Increase y-yN

Gurus Latest Trades with CRME

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CRMEJulian Robertson 2012-12-31 Sold Out -0.11%$1.25 - $2.5
($1.57)
$ 5.47248%Sold Out0
CRMEJulian Robertson 2011-12-31 Reduce-0.48%$9.35 - $17.85
($13.14)
$ 5.47-58%Reduce -18.26%319,221
CRMEGeorge Soros 2011-12-31 Sold Out -0.0008%$9.35 - $17.85
($13.14)
$ 5.47-58%Sold Out0
CRMEJulian Robertson 2011-09-30 Reduce-0.69%$16.45 - $27.95
($19.93)
$ 5.47-73%Reduce -22.89%390,518
CRMEGeorge Soros 2011-09-30 Add$16.45 - $27.95
($19.93)
$ 5.47-73%Add 4.55%2,760
CRMEGeorge Soros 2011-06-30 Buy $19.25 - $28.85
($23.59)
$ 5.47-77%New holding2,640
CRMEJulian Robertson 2011-03-31 Add0.16%$21.3 - $34.95
($29.29)
$ 5.47-81%Add 6.15%506,468
CRMEJulian Robertson 2010-12-31 Add0.34%$23 - $32.75
($27.99)
$ 5.47-80%Add 9.55%477,123
CRMEGeorge Soros 2010-12-31 Sold Out $23 - $32.75
($27.99)
$ 5.47-80%Sold Out0
CRMEJulian Robertson 2010-09-30 Add0.4%$29.85 - $46.55
($36.3)
$ 5.47-85%Add 10.01%435,523
CRMEGeorge Soros 2010-09-30 Reduce$29.85 - $46.55
($36.3)
$ 5.47-85%Reduce -3.67%2,100
CRMEJulian Robertson 2010-06-30 Buy 3.53%$33.05 - $43.4
($40.09)
$ 5.47-86%New holding395,881
CRMEGeorge Soros 2010-06-30 Buy $33.05 - $43.4
($40.09)
$ 5.47-86%New holding2,180
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CRME is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


CRME: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Archibald, JenniferSenior Officer 2014-09-08Buy75$7.29-24.97view
Archibald, JenniferSenior Officer 2014-09-05Buy4,100$7.25-24.55view
Archibald, JenniferSenior Officer 2014-09-05Buy100$7.22-24.24view
Archibald, JenniferSenior Officer 2014-09-05Buy3,259$6.7-18.36view
Hunter, William L.Director, Senior Officer 2014-09-05Buy31,000$6.74-18.84view
Hunter, William L.Director, Senior Officer 2014-09-04Buy19,000$6.65-17.74view
RIEDER, ROBERTDirector, Director or Senior Officer of Insider or 2014-06-27Sell2,000$8.65-36.76view
RIEDER, ROBERTDirector, Director or Senior Officer of Insider or 2014-06-26Sell1,500$8.65-36.76view
RIEDER, ROBERTDirector, Director or Senior Officer of Insider or 2014-06-25Sell300$8.63-36.62view
RIEDER, ROBERTDirector, Director or Senior Officer of Insider or 2014-06-25Sell2,000$8.64-36.69view

Press Releases about CRME :

Quarterly/Annual Reports about CRME:

    News about CRME:

    Articles On GuruFocus.com
    Julian Robertson’s "smart idea, grounded on exhaustive research, followed by a big bet" Jun 24 2011 
    Julian Robertson’s Tiger Management Q1 Portfolio Update May 16 2011 
    Julian Robertson Keeps Buying CRME, Selling AAPL Apr 13 2011 
    More Word of Wisdom from Julian Robertson; Top 2Q10 Purchases: GOOG, EBAY, AAPL, CRME, GS Nov 04 2010 

    More From Other Websites
    Cardiome Announces Filing of Orphan Drug Application for Oral Vernakalant with U.S. FDA Jan 27 2016
    Cardiome Announces Filing of Orphan Drug Application for Oral Vernakalant with U.S. FDA Jan 27 2016
    Cardiome Announces Filing of Orphan Drug Application for Oral Vernakalant with U.S. FDA Jan 27 2016
    Cardiome Announces the Launch of ESMOCARD LYO in Belgium Jan 21 2016
    Cardiome Announces the Launch of ESMOCARD LYO in Belgium Jan 21 2016
    Cardiome Announces the Launch of ESMOCARD LYO in Belgium Jan 21 2016
    Cardiome announces filing of marketing authorization application for intravenous vernakalant in the... Jan 13 2016
    Cardiome announces filing of marketing authorization application for intravenous vernakalant in the... Jan 13 2016
    Cardiome announces filing of marketing authorization application for intravenous vernakalant in the... Jan 13 2016
    Cardiome Announces Share Purchase Agreement with Lincoln Park Capital Fund, LLC Jan 12 2016
    Cardiome Announces Share Purchase Agreement with Lincoln Park Capital Fund, LLC Jan 12 2016
    Cardiome Announces Share Purchase Agreement with Lincoln Park Capital Fund, LLC Jan 12 2016
    Cardiome/SteadyMed's PAH Drug Approved for Review in EU Jan 07 2016
    Cardiome and SteadyMed Announce Decision for Centralized Review of Trevyent® by the European... Jan 06 2016
    Cardiome and SteadyMed Announce Decision for Centralized Review of Trevyent® by the European... Jan 06 2016
    Cardiome and SteadyMed Announce Decision for Centralized Review of Trevyent® by the European... Jan 06 2016
    Cardiome and SteadyMed Announce Decision for Centralized Review of Trevyent® by the European... Jan 06 2016
    Cardiome and SteadyMed Announce Decision for Centralized Review of Trevyent® by the European... Jan 06 2016
    Cardiome Enters Commercialization Agreement with Chong Kun Dang for BRINAVESS® in South Korea Jan 05 2016
    Cardiome Enters Commercialization Agreement with Chong Kun Dang for BRINAVESS® in South Korea Jan 05 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK